<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="141068ee-85a2-40e4-a915-9ac149a5a57a"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use Desoximetasone Topical Spray, 0.25% safely and effectively. See full prescribing information for Desoximetasone Topical Spray, 0.25%. DESOXIMETASONE Topical Spray, 0.25% <br/>Initial U.S. Approval: 1977</title>
   <effectiveTime value="20250320"/>
   <setId root="e4b648f4-c65d-44b3-a97a-657730f65322"/>
   <versionNumber value="11"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="089153071" root="1.3.6.1.4.1.519.1"/>
            <name>Lupin Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="080038238" root="1.3.6.1.4.1.519.1"/>
                  <name>LUPIN INC.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="650595213" root="1.3.6.1.4.1.519.1"/>
                        <name>LUPIN LIMITED</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-944" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-944" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3d030028-98b4-429f-a09f-0e575d365b4c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250320"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68180-944" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Desoximetasone</name>
                        <formCode code="C42989" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SPRAY"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Desoximetasone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="2.5" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4E07GXB7AU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DESOXIMETASONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="4E07GXB7AU" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DESOXIMETASONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1P9D0Z171K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYLATED HYDROXYTOLUENE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="P7E6YFV72X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIISOPROPYL ADIPATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="BZ1R15MTK7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEVOMENTHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C9H2L21V7U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEDIUM-CHAIN TRIGLYCERIDES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T5L8T28FGP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MINERAL OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="06XEA2VD56" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBITAN MONOOLEATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68180-944-33" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180720"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68180-944-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20400101"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="50" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68180-944-22" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20400101"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA208124" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180720"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID106">
               <id root="55f58193-1684-4d4e-a92a-ead08550e07b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20150618"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID110">Desoximetasone topical spray, 0.25% is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older (<linkHtml href="#ID106">1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID107">
                     <id root="ef940a8e-2722-4ed1-a569-f8817f75143f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID108">Desoximetasone topical spray, 0.25% is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older. </paragraph>
                     </text>
                     <effectiveTime value="20150618"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID111">
               <id root="37b0261e-7b65-4ae0-96db-05fe08550141"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20211122"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID115" styleCode="Disc">
                           <item>Apply a thin film to the affected skin areas twice daily. Rub in gently. (<linkHtml href="#ID111">2</linkHtml>)</item>
                           <item>Discontinue treatment when control is achieved. (<linkHtml href="#ID111">2</linkHtml>)</item>
                           <item>Treatment beyond 4 weeks is not recommended. (<linkHtml href="#ID111">2</linkHtml>)</item>
                           <item>Do not use if atrophy is present at the treatment site. (<linkHtml href="#ID111">2</linkHtml>)</item>
                           <item>Do not use with occlusive dressings, unless directed by the physician (<linkHtml href="#ID111">2</linkHtml>)</item>
                           <item>Avoid use on the face, axilla or groin. (<linkHtml href="#ID111">2</linkHtml>)</item>
                           <item>Not for oral, ophthalmic, or intravaginal use. (<linkHtml href="#ID111">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID112">
                     <id root="8644ae71-6d22-47e3-b56c-c7523961a072"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID113">Apply desoximetasone topical spray, 0.25% as a thin film to the affected skin areas twice daily. Rub in gently. </paragraph>
                        <paragraph>Do not bandage or otherwise cover or wrap the treated skin unless directed by the physician. </paragraph>
                        <paragraph>Discontinue treatment when control is achieved. </paragraph>
                        <paragraph>Treatment beyond 4 weeks is not recommended. </paragraph>
                        <paragraph>Do not use if atrophy is present at the treatment site. </paragraph>
                        <paragraph>Avoid use on the face, axilla or groin. </paragraph>
                        <paragraph>Desoximetasone topical spray, 0.25% is for external use only. It is not for oral, ophthalmic, or intravaginal use. </paragraph>
                     </text>
                     <effectiveTime value="20211117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID116">
               <id root="8ab7256d-c8b5-4267-bf3d-0db3f3cd84fc"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <effectiveTime value="20150618"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID120">Spray, 0.25% w/w (<linkHtml href="#ID116">3</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID117">
                     <id root="bca2a601-ddf0-42ec-8181-3089736f5b7d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID118">Topical Spray, 0.25%. Each gram of desoximetasone topical spray contains 2.5 mg of desoximetasone USP in a clear, colorless liquid. </paragraph>
                     </text>
                     <effectiveTime value="20150618"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID121">
               <id root="d9a644b4-009e-4c79-aab0-24301b02808d"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20211122"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID125">None (<linkHtml href="#ID121">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID122">
                     <id root="62db3b14-b91d-47df-9755-4c6bf5501c4a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID123">None </paragraph>
                     </text>
                     <effectiveTime value="20150618"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID126">
               <id root="6223541d-771e-499c-a957-db743673268f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20211122"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID138" styleCode="Disc">
                           <item>Effect on Endocrine System: Desoximetasone topical spray, 0.25% can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency during or after treatment. (<linkHtml href="#ID127">5.1</linkHtml>)</item>
                           <item>Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can result from systemic absorption of topical corticosteroids. (<linkHtml href="#ID127">5.1</linkHtml>)</item>
                           <item>Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. (<linkHtml href="#ID127">5.1</linkHtml>)</item>
                           <item>Modify use if HPA axis suppression develops. (<linkHtml href="#ID127">5.1</linkHtml>)</item>
                           <item>High potency corticosteroids, large treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure and young age may predispose patients to HPA axis suppression. (<linkHtml href="#ID127">5.1</linkHtml>)</item>
                           <item>Pediatric patients may be more susceptible to systemic toxicity when treated with topical corticosteroids. Safety and effectiveness have not been established in pediatric patients and use in pediatric patients is not recommended. (<linkHtml href="#ID127">5.1</linkHtml>, <linkHtml href="#ID150">8.4</linkHtml>)</item>
                           <item>Ophthalmic Adverse Reactions: Topical corticosteroid products may increase the risk of cataracts and glaucoma. If visual symptoms occur, consider referral to an ophthalmologist. (<linkHtml href="#ID217">5.3</linkHtml>.).</item>
                           <item>Flammability: Desoximetasone topical spray, 0.25% is flammable; keep away from heat or flame. (<linkHtml href="#ID135">5.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID127">
                     <id root="6f26055b-c389-4a3d-a2fc-aa7bcdcc0502"/>
                     <title>5.1 Effect on Endocrine System</title>
                     <text>
                        <paragraph ID="ID128">Desoximetasone topical spray, 0.25% is a topical corticosteroid that has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis. </paragraph>
                        <paragraph>Systemic absorption of topical corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid. </paragraph>
                        <paragraph>In a study including 21 evaluable subjects 18 years of age or older with moderate to severe plaque psoriasis, adrenal suppression was identified in 1 out of 12 subjects having involvement of 10 to 15% of body surface area (BSA) and 2 out of 9 subjects having involvement of &gt;15% of BSA after treatment with desoximetasone topical spray, 0.25% twice a day for 28 days. <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID165">12.2</linkHtml>)]</content> </paragraph>
                        <paragraph>Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of high potency steroids, larger treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure and young age.</paragraph>
                        <paragraph>An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression. </paragraph>
                        <paragraph>If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids. </paragraph>
                        <paragraph>Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. </paragraph>
                        <paragraph>Use of more than one corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure. </paragraph>
                        <paragraph>Pediatric patients may be more susceptible to systemic toxicity from use of topical corticosteroids. Use in patients under 18 years of age is not recommended due to  numerically high rates of HPA axis suppression (the safety and effectiveness of desoximetasone topical spray, 0.25% have not been established in pediatric patients)  <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID150">8.4</linkHtml>)</content> <content styleCode="italics">and Clinical Pharmacology (<linkHtml href="#ID165">12.2</linkHtml>)] </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID129">
                     <id root="54060a28-d446-46dd-bc2a-ad2c68f2c5af"/>
                     <title>5.2 Local Adverse Reactions with Topical Corticosteroids</title>
                     <text>
                        <paragraph ID="ID130">Local adverse reactions may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. Some local adverse reactions may be irreversible. </paragraph>
                     </text>
                     <effectiveTime value="20150618"/>
                  </section>
               </component>
               <component>
                  <section ID="ID217">
                     <id root="8c983638-aba6-406e-87b8-89107e6fe551"/>
                     <title>5.3 Ophthalmic Adverse Reactions</title>
                     <text>
                        <paragraph ID="ID218">Use of topical corticosteroids, including Desoximetasone topical spray, 0.25%, may increase the risk of posterior subcapsular cataracts and glaucoma. Cataracts and glaucoma have been reported with the postmarketing use of topical corticosteroid products <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID219">6.2</linkHtml>)]</content>. Avoid contact of Desoximetasone topical spray, 0.25% with eyes. Desoximetasone topical spray, 0.25% may cause eye irritation. Advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation.</paragraph>
                     </text>
                     <effectiveTime value="20211118"/>
                  </section>
               </component>
               <component>
                  <section ID="ID131">
                     <id root="e70079a5-a3c8-4718-8ff0-bf57a034af4b"/>
                     <title>5.4 Allergic Contact Dermatitis with Topical Corticosteroids</title>
                     <text>
                        <paragraph ID="ID132">Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a failure to heal rather than a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing. </paragraph>
                     </text>
                     <effectiveTime value="20211117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID133">
                     <id root="a1ea8b36-9141-416f-9b28-39032be11401"/>
                     <title>5.5 Concomitant Skin Infections</title>
                     <text>
                        <paragraph ID="ID134">Concomitant skin infections should be treated with an appropriate antimicrobial agent. </paragraph>
                        <paragraph>If the infection persists, desoximetasone topical spray, 0.25% should be discontinued until the infection has been adequately treated. </paragraph>
                     </text>
                     <effectiveTime value="20211117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID135">
                     <id root="6e640a0a-2c67-4f63-9f8e-be67a4f717f4"/>
                     <title>5.6 Flammability</title>
                     <text>
                        <paragraph ID="ID136">Desoximetasone topical spray, 0.25% is flammable; keep away from heat or flame. </paragraph>
                     </text>
                     <effectiveTime value="20211117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID139">
               <id root="4b5706ee-0b8b-412e-938c-b924db88fb78"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20211130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID144">The most common adverse reactions (≥ 1%) are application site dryness, application site irritation and application site pruritus. (<linkHtml href="#ID140">6.1</linkHtml>) </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID140">
                     <id root="e36acfc1-8d83-4161-b39e-495c05655190"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph ID="ID141">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In randomized, multicenter, prospective vehicle-controlled clinical trials, subjects with moderate to severe plaque psoriasis of the body applied desoximetasone topical spray, 0.25% or vehicle spray twice daily for 4 weeks. A total of 149 subjects applied desoximetasone topical spray, 0.25%. </paragraph>
                        <paragraph>Adverse reactions that occurred in ≥ 1% of subjects treated with desoximetasone topical spray, 0.25% are presented in Table 1.</paragraph>
                        <table ID="ID210" width="607" styleCode="Noautorules">
                           <caption>  Table 1. Number (%) of Subjects with Adverse Reactions Occurring in ≥ 1% Another less common adverse reaction (&lt;1% but &gt;0.1%) was folliculitis.</caption>
                           <col width="253"/>
                           <col width="228"/>
                           <col width="126"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule Lrule"/>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Desoximetasone Topical Spray, 0.25% <content styleCode="italics">b.i.d </content> (N = 149)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Vehicle spray </content>
                                    <br/>
                                    <content styleCode="bold">
                                       <content styleCode="italics">b.i.d. </content>
                                    </content>
                                    <content styleCode="bold"> (N = 135)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule Rrule" align="left"> Number of Subjects with Adverse Reactions <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 13 (8.7%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 18 (13.3%) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule Rrule" align="left"> Application site dryness <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 4 (2.7%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 7 (5.2%) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule Rrule" align="left"> Application site irritation <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 4 (2.7%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5 (3.7%) <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule Rrule" align="left"> Application site pruritus <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 (2.0%) <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5 (3.7%) <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID224">Another less common adverse reaction (&lt;1% but &gt;0.1%) was folliculitis.</paragraph>
                     </text>
                     <effectiveTime value="20211130"/>
                  </section>
               </component>
               <component>
                  <section ID="ID219">
                     <id root="416d003d-5e89-475a-b7f7-56f3b954c6ad"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID220">Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Postmarketing reports for local adverse reactions to topical corticosteroids included atrophy, striae, telangiectasias, itching, dryness, hypopigmentation, perioral dermatitis, secondary infection, and miliaria.</paragraph>
                        <paragraph>Ophthalmic adverse reactions of cataracts, glaucoma, and increased intraocular pressure have been reported during use of topical corticosteroids.</paragraph>
                     </text>
                     <effectiveTime value="20211117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID145">
               <id root="e6f8035f-bee8-4f88-826c-fee921b37951"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20211130"/>
               <component>
                  <section ID="ID146">
                     <id root="a145c532-c50e-46e0-8ca7-fdbb7a7d2752"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID147">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no available data on desoximetasone use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Observational studies suggest maternal use of high to super-high potency topical steroids, including Desoximetasone topical spray, 0.25%, may be associated with an increased risk of low birthweight infants <content styleCode="italics">(see Data)</content>. Advise pregnant woman that  Desoximetasone topical spray, 0.25% may increase  the potential risk of low birth weight infants and to use Desoximetasone topical spray, 0.25% on the smallest area of skin and for the shortest duration possible.</paragraph>
                        <paragraph>Desoximetasone has been shown to cause malformations and be embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration at doses 3 to 30 times the human dose of Desoximetasone topical spray, 0.25% based on a body surface area comparison. </paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>Data</paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>Available observational studies in pregnant women did not identify a drug-associated risk of major birth defects, preterm delivery, or fetal mortality with the use of topical corticosteroids of any potency. However, when the dispensed amount of high to super-high potency topical corticosteroids exceeded 300g during the entire pregnancy, maternal use was associated with an increased risk of low birth weight in infants.</paragraph>
                     </text>
                     <effectiveTime value="20211130"/>
                  </section>
               </component>
               <component>
                  <section ID="ID148">
                     <id root="8f3e739b-c92a-4123-8fe3-5b7e3f7adf01"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID149">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There is no information on the presence of topically administered desoximetasone in human milk, the effects on the breastfed infant, or the effects on milk production.</paragraph>
                        <paragraph>It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for desoximetasone topical spray, 0.25% and any potential adverse effects on the breastfed infant from desoximetasone topical spray, 0.25% or from the underlying maternal condition. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>To minimize potential exposure to the breastfed infant via breast milk, use desoximetasone topical spray, 0.25% on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women not to apply desoximetasone topical spray, 0.25% directly to the nipple and areola to avoid direct infant exposure <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID127">5.1</linkHtml>) and Use in Specific Populations (<linkHtml href="#ID150">8.4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20211201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID150">
                     <id root="e33f0c56-0ec6-43e6-a475-689e3aca907c"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID151">The safety and effectiveness of desoximetasone topical spray, 0.25% have not been established in pediatric patients for the treatment of plaque psoriasis. Desoximetasone topical spray, 0.25% is not recommended for use in patients less than 18 years of age due to the high incidence of HPA axis suppression observed <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID127">5.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hypothalamic-Pituitary Adrenal (HPA) Axis Suppression</content>
                        </paragraph>
                        <paragraph>The HPA axis suppression potential of desoximetasone topical spray, 0.25% was assessed in an open-label, sequential cohort, safety trial in 129 subjects 2 years to less than 18 years of age with moderate to severe plaque psoriasis defined as a Physician Global Assessment (PGA) score of ≥3 with involvement of at least 10% of their body surface area (excluding the face and scalp). In total, 100 pediatric subjects were evaluated for HPA axis function via cosyntropin stimulation testing at baseline and following 4 weeks of twice daily application of desoximetasone topical spray, 0.25%. Overall, 36% of pediatric subjects 2 years to less than 18 years of age demonstrated HPA axis suppression defined as a serum cortisol level ≤ 18 mcg/dL 30-minutes post cosyntropin stimulation. The proportion of subjects demonstrating HPA axis suppression was 35.0% in Cohort 1 (12 years to less than 18 years of age) and 43.3% in Cohort 2 (6 years to less than 12 years of age). Trial enrollment in the youngest cohort (2 years to less than 6 years of age) was discontinued early due to high incidence of HPA axis suppression observed in the two oldest cohorts (6 years to less than 18 years of age) <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID165">12.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are therefore at greater risk of adrenal insufficiency during and/or after withdrawal of treatment. Adverse reactions including striae have been reported with inappropriate use of topical corticosteroids in infants and children. </paragraph>
                        <paragraph>HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.</paragraph>
                     </text>
                     <effectiveTime value="20211118"/>
                  </section>
               </component>
               <component>
                  <section ID="ID152">
                     <id root="7f30828c-7eba-4f53-802f-b913151eaef9"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID153">Clinical studies of desoximetasone topical spray, 0.25% did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </paragraph>
                     </text>
                     <effectiveTime value="20150618"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID154">
               <id root="93e10808-4806-4664-8596-18dd2f5139c6"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <effectiveTime value="20171123"/>
               <component>
                  <section ID="ID155">
                     <id root="d9cfed94-4d2a-4a6e-b6fd-18af49248cd9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID156">Desoximetasone topical spray, 0.25% can be absorbed in sufficient amounts to produce systemic effects. <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID127">5.1</linkHtml>)]</content> </paragraph>
                     </text>
                     <effectiveTime value="20171123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID157">
               <id root="4f7dff7b-a2e0-4d94-8ab2-c22edde79158"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <effectiveTime value="20250320"/>
               <component>
                  <section ID="ID158">
                     <id root="c3bf2858-6af5-44a0-b7f7-2b38e55ad533"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID159">Desoximetasone topical spray, 0.25% for dermatologic use contains desoximetasone as the active ingredient. Desoximetasone is a corticosteroid with the chemical name of pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16-methyl-, (11ß,16α)-. Desoximetasone has the molecular formula of C<sub>22</sub>H<sub>29</sub>FO<sub>4</sub> and a molecular weight of 376.47. The CAS Registry Number is 382-67-2. The structural formula is:</paragraph>
                        <renderMultiMedia referencedObject="MM1"/>
                        <paragraph ID="ID161">Each gram of desoximetasone topical spray, 0.25% contains 2.5 mg of Desoximetasone USP in a clear, colorless liquid with the following inactive ingredients: butylated hydroxytoluene, citric acid anhydrous, diisopropyl adipate, isopropyl alcohol (23.4%), L-menthol, medium-chain triglycerides, mineral oil and sorbitan monooleate. Desoximetasone topical spray, 0.25% is co-packaged with a manual spray pump for installation by the pharmacist prior to dispensing to patients. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM1">
                     <text>structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="141068ee-85a2-40e4-a915-9ac149a5a57a-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID162">
               <id root="62a64f71-9558-4aba-8527-f9e734f14505"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20211118"/>
               <component>
                  <section ID="ID163">
                     <id root="85ffc723-aab5-41ed-a4bb-7131d283eb67"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID164">Corticosteroids play a role in cellular signaling, immune function, inflammation and protein regulation; however, the precise mechanism of action in psoriasis is unknown. </paragraph>
                     </text>
                     <effectiveTime value="20150618"/>
                  </section>
               </component>
               <component>
                  <section ID="ID165">
                     <id root="516df91e-4856-467e-b8c5-08a43d400b25"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID166">
                           <content styleCode="underline">Vasoconstrictor Assay</content>
                        </paragraph>
                        <paragraph>Vasoconstrictor studies performed with desoximetasone topical spray, 0.25% in healthy subjects indicate that it is in the high to super-high range of potency as compared with other topical corticosteroids. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hypothalamic-Pituitary Adrenal (HPA) Axis Suppression </content>
                        </paragraph>
                        <paragraph>The potential for hypothalamic-pituitary-adrenal (HPA) axis suppression was evaluated in two trials. Desoximetasone topical spray, 0.25% was applied twice a day for 28 days and HPA axis suppression was defined as serum cortisol level ≤18 mcg/dL 30-min post cosyntropin stimulation.  In the first trial, out of 24 adult subjects with moderate to severe plaque psoriasis, 21. subjects had evaluable serum cortisol levels. The proportion of subjects demonstrating HPA axis suppression was 8.3% (1 out of 12) in subjects having psoriasis involvement of 10-15% of body surface area (BSA), and 22.2% (2 out of 9) in subjects having psoriasis involvement of &gt; 15% of their BSA. In the 2 subjects with available follow-up values, suppression reversed 28 days after the end of treatment. </paragraph>
                        <paragraph>In another trial, the HPA axis suppression was evaluated in 106 pediatric subjects with moderate to severe plaque psoriasis. One hundred subjects had evaluable serum cortisol levels. The proportion of subjects demonstrating HPA axis suppression was 35.0% (21 out of 60) in Cohort 1 (12 years to less than 18 years of age, with a mean baseline BSA involvement of 16%), and 43.3% (13 out of 30) in Cohort 2 (6 years to less than 12 years of age, with a mean baseline BSA involvement of 19%). Trial enrollment in the youngest cohort (2 years to less than 6 years of age) was discontinued early due to high incidence of HPA axis suppression observed in the two oldest cohorts (6 years to less than 18 years of age). The overall HPA axis suppression rate was 36% in pediatric subjects 2 years to less than 18 years of age. Due to high incidence of HPA axis suppression observed from this trial, desoximetasone topical spray, 0.25% is not recommended for use in pediatric patients less than 18 years of age <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID150">8.4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20211118"/>
                  </section>
               </component>
               <component>
                  <section ID="ID167">
                     <id root="a5342d19-b932-4731-851a-fc95f94bf5bd"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID168">The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. </paragraph>
                        <paragraph>Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile. </paragraph>
                        <paragraph>Plasma concentrations of desoximetasone were measured at two single random time points in the HPA axis suppression trial in 24 adult subjects with psoriasis <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID165">12.2</linkHtml>)]</content>. The mean (% Coefficient of Variation) concentration of desoximetasone was 449 pg/mL (86%) at Day 14 and 678 pg/mL (135%) at Day 28. The concentration time profile following application of desoximetasone topical spray, 0.25% is not known. </paragraph>
                        <paragraph>In the pediatric HPA axis suppression trial, plasma concentrations of desoximetasone were measured in a subset of subjects in Cohorts 1 and 2 <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID165">12.2</linkHtml>)]</content>. High inter subject variability in plasma concentrations was observed in both cohorts. The mean (% Coefficient of Variation) maximum concentration on Day 29 was 1881 pg/mL (127%) in Cohort 1 (n=11) and 1116 pg/mL (94%) in Cohort 2 (n=8).</paragraph>
                     </text>
                     <effectiveTime value="20211118"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID169">
               <id root="d5b1b30c-5e4e-410e-9f2e-233c4d140bf5"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20180702"/>
               <component>
                  <section ID="ID170">
                     <id root="a41f4e92-af49-4742-b98f-f30b4f3ac33b"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID171">Long-term animal studies have not been performed to evaluate the carcinogenic potential of desoximetasone topical spray, 0.25%. </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>In a 13-week repeat-dose toxicity study in rats, topical administration of desoximetasone spray at concentrations of 0.001, 0.005 and 0.02% BID (which corresponds to dose levels of 0.01, 0.05, or 0.2 mg/kg/dose BID, respectively) resulted in a toxicity profile consistent with long-term exposure to corticosteroids, including adrenal atrophy and histopathological changes in several organ systems indicative of severe immune suppression. A no observable adverse effect level (NOAEL) could not be determined in this study. Although the clinical relevance of the findings in animals to humans is not clear, sustained glucocorticoid-related immune suppression may increase the risk of infection and possibly the risk for carcinogenesis.</paragraph>
                        <paragraph>Desoximetasone revealed no evidence of mutagenic or clastogenic potential based on the results of two <content styleCode="italics">in vitro </content>genotoxicity tests (Ames assay and Chinese hamster ovary cell chromosome aberration assay) and one <content styleCode="italics">in vivo </content>genotoxicity test (mouse bone marrow micronucleus assay). </paragraph>
                        <paragraph>No evidence of impairment of male or female fertility was observed at subcutaneous desoximetasone doses up to 0.1 mg/kg/day (0.6 mg/m<sup>2</sup>/day) in Sprague-Dawley rats. </paragraph>
                        <paragraph> </paragraph>
                     </text>
                     <effectiveTime value="20180702"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID172">
               <id root="b098e45b-4e93-45bb-b8bc-e4993ddddd99"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20211117"/>
               <component>
                  <section ID="ID173">
                     <id root="28e090d1-e259-48ff-a6f4-c891247be8c1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID174">Two multi-center, randomized, double-blind, vehicle- controlled clinical trials were conducted in 239 subjects aged 18 years and older with moderate to severe plaque psoriasis of the body. In both trials, randomized subjects applied desoximetasone topical spray, 0.25% or vehicle spray to the affected areas twice daily for 4 weeks. Enrolled subjects had a minimum body surface area of involvement of 10%, and a Physician's Global Assessment score (PGA) of 3 (moderate) or 4 (severe). </paragraph>
                        <paragraph>Efficacy was assessed at Week 4 as the proportion of subjects who were considered a Clinical Success ("clear" (0) or "almost clear" (1) according to the PGA scale). Table 2 presents the efficacy results.</paragraph>
                        <table ID="ID211" width="583" styleCode="Noautorules">
                           <caption>  Table 2. Number of Subjects (%) with Clinical Success (scored as clear or almost clear) at Week 4. </caption>
                           <col width="115"/>
                           <col width="150"/>
                           <col width="72"/>
                           <col width="144"/>
                           <col width="102"/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Paramete</content>
                                    <content styleCode="bold"> r</content>
                                    <br/>
                                 </td>
                                 <td colspan="2" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Trial 1</content>
                                    <br/>
                                 </td>
                                 <td colspan="2" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Trial </content>
                                    <content styleCode="bold"> 2</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Desoximetasone Topical Spray, 0.25% </content>
                                    <br/>
                                    <content styleCode="bold"> N=59</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Vehicle </content>
                                    <br/>
                                    <content styleCode="bold"> N=60</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Desoximetasone Topical Spray, 0.25%</content>
                                    <br/>
                                    <content styleCode="bold"> N=60</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Vehicle </content>
                                    <br/>
                                    <content styleCode="bold"> N=60</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Clinical Success </content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 18 (30.5%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3 (5.0%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 32 (53.3%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 11 (18.3%)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20211117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID176">
               <id root="6d8cec7e-702d-4d7a-943f-837c18294be8"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20211117"/>
               <component>
                  <section ID="ID177">
                     <id root="1d726818-89a5-4ae4-abb0-6b40f6105d37"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied/Storage</title>
                     <text>
                        <paragraph ID="ID178">Desoximetasone topical spray, 0.25% is a clear, colorless liquid supplied in white, opaque bottles with white, opaque screw caps in the following sizes:</paragraph>
                        <list listType="unordered" ID="ID179" styleCode="Disc">
                           <item>30 mL (NDC 68180-944-11)</item>
                           <item>50 mL (NDC 68180-944-22)</item>
                           <item>100 mL (NDC 68180-944-33)</item>
                        </list>
                        <paragraph ID="ID180">Store at controlled room temperature between 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. Spray is flammable; avoid heat, flame or smoking when using this product. </paragraph>
                        <paragraph>Each unit is co-packaged with a manual spray pump for installation by the pharmacist. </paragraph>
                     </text>
                     <effectiveTime value="20211117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID181">
                     <id root="75d7a6fd-46cd-43b2-8e40-9bc8c4536aea"/>
                     <title>16.2 Instructions for the Pharmacist</title>
                     <text>
                        <list listType="ordered" ID="ID182">
                           <item>Remove the spray pump from the wrapper</item>
                           <item>Remove and discard the cap from the bottle</item>
                           <item>Keeping the bottle vertical, insert the spray pump into the bottle and turn clockwise until well-fastened</item>
                           <item>Dispense the bottle with the spray pump inserted</item>
                           <item>      Label the bottle with "discard the product 30 days after dispensing"</item>
                        </list>
                     </text>
                     <effectiveTime value="20211117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID183">
               <id root="20e094e6-2c75-4212-97fa-7318c3ec28b1"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20250320"/>
               <component>
                  <section ID="ID184">
                     <id root="43150798-4d22-4d69-9474-ea5e1887249c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID185">See FDA-approved patient labeling (Patient Information and Instructions for Use) </paragraph>
                        <paragraph>Inform patients of the following: </paragraph>
                        <list listType="unordered" ID="ID226" styleCode="Disc">
                           <item>Use this medication as directed      by the physician. Do not use this medication for any disorder other than      that for which it was prescribed.</item>
                           <item>Desoximetasone topical spray,      0.25% is for external use only.</item>
                           <item>Avoid contact with eyes and use      on the face, axilla or groin.</item>
                           <item>To minimize the risk of adverse      reactions:<list listType="unordered" styleCode="Circle">
                                 <item>do not bandage or otherwise      cover or wrap the treated skin so as to be occlusive.</item>
                                 <item>discontinue therapy when      control is achieved. If no improvement is seen within 4 weeks, contact the      physician.</item>
                                 <item>do not use other      corticosteroid-containing products with desoximetasone topical spray,      0.25% without first consulting with the physician.</item>
                              </list>
                           </item>
                           <item>Advise patients that      desoximetasone topical spray, 0.25%, may require periodic evaluation for      HPA axis suppression. Topical corticosteroids may have other endocrine      effects. [see Warnings and Precautions (<linkHtml href="#ID127">5.1</linkHtml>)].</item>
                           <item>Advise women to use      desoximetasone topical spray, 0.25% on the smallest area of skin and for      the shortest duration possible while pregnant or breastfeeding. Advise      breastfeeding woman not to apply desoximetasone topical spray, 0.25%      directly to the nipple and areola to avoid direct infant exposure [see Use      in Specific Populations (<linkHtml href="#ID146">8.1 </linkHtml>and <linkHtml href="#ID148">8.2</linkHtml>].</item>
                           <item>Report any      signs of local or systemic adverse reactions including any visual symptoms      to the physician.</item>
                           <item>This      medication is flammable; avoid heat, flame, or smoking when applying this      product.</item>
                           <item>Discard this      product 30 days after dispensed by pharmacist.</item>
                        </list>
                        <paragraph ID="ID187">LUPIN and the <renderMultiMedia referencedObject="IMGID1871"/> are registered trademarks of Lupin Pharmaceuticals, Inc.</paragraph>
                        <paragraph>Manufactured for:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                        </paragraph>
                        <paragraph>Naples, FL 34108 </paragraph>
                        <paragraph>United States</paragraph>
                        <paragraph>Manufactured by:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Lupin Limited</content>
                        </paragraph>
                        <paragraph>Pithampur (M.P.) – 454 775</paragraph>
                        <paragraph>India</paragraph>
                        <paragraph>Revised: October 2024</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="IMGID1871">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="141068ee-85a2-40e4-a915-9ac149a5a57a-187-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID208">
               <id root="2417387e-a1a5-426f-a310-3f80ce4d574c"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table ID="ID216" width="590" styleCode="Noautorules">
                     <col width="590"/>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> PATIENT INFORMATION</content>
                              <br/>
                              <content styleCode="bold"> Desoximetasone Topical Spray, 0.25%</content>
                              <br/>
                              <content styleCode="bold"> (des-OX-i-MET-a-sone)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Important information: Desoximetasone topical spray, 0.25% is for use on skin (topical) only</content> . Do not get desoximetasone topical spray, 0.25% near or in your mouth, eyes or vagina.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> What is Desoximetasone Topical Spray, 0.25%? </content>
                              <br/> Desoximetasone topical spray, 0.25% is a prescription corticosteroid medicine used to treat plaque psoriasis of the body in people 18 years of age and older. <br/> It is not known if desoximetasone topical spray, 0.25% is safe and effective in children under 18 years of age. Desoximetasone topical spray, 0.25% is not recommended for use in children under 18 years of age. <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Before you use Desoximetasone Topical Spray, 0.25%, tell your doctor about all of your medical conditions, including if you: </content>
                              <br/>           have had irritation or other skin reaction to a steroid medicine in the past.<br/>           have a skin infection. You may need medicine to treat the skin infection before you use desoximetasone topical spray, 0.25%. <br/>           have thinning of the skin (atrophy) at the treatment site <br/>           have adrenal gland problems<br/>           have diabetes <br/>           liver problems<br/>           are pregnant or plan to become pregnant. It is not known if desoximetasone topical spray, 0.25% will harm your unborn baby. Desoximetasone topical spray, 0.25%. may increase your chance of having a low birthweight baby. If you use desoximetasone topical spray, 0.25%. during pregnancy, use desoximetasone topical spray, 0.25%. on the smallest area of the skin and for the shortest time needed.<br/>           are breastfeeding or plan to breastfeed. It is not known if desoximetasone passes into your breast milk. If you use desoximetasone topical spray, 0.25% and breastfeed, use desoximetasone topical spray, 0.25% on the smallest area of the skin and for the shortest time needed. Do not apply desoximetasone topical spray, 0.25% directly to the nipple and areola to avoid contact with your baby. <br/>
                              <content styleCode="bold"> Tell your doctor about all the medicines you take </content> including prescription and over-the-counter medicines, vitamins and herbal supplements. Especially tell your doctor if you take other corticosteroid medicines by mouth or use other products on your skin that contain corticosteroids. Do not use other products containing a corticosteroid medicine while using desoximetasone topical spray, 0.25% without talking to your doctor first.<br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> What should I avoid while using Desoximetasone Topical Spray, 0.25%? </content>
                              <br/>
                              <content styleCode="bold"> Desoximetasone Topical Spray, 0.25% is flammable. </content> Avoid heat, flames or smoking while applying desoximetasone topical spray, 0.25% to your skin.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> How should I use Desoximetasone Topical Spray, 0.25%? </content>
                              <br/>
                              <content styleCode="bold"> See the "Instructions for Use" for detailed information about the right way to apply desoximetasone topical spray, 0.25%.</content>
                              <br/>           Use desoximetasone topical spray, 0.25% exactly as your doctor tells you to use it. <br/>           Your doctor should tell you how much desoximetasone topical spray, 0.25% to use and where to use it.<br/>           Apply desoximetasone topical spray, 0.25% to the affected skin areas 2 times a day and rub it in gently. <br/>           Do not bandage, cover, or wrap the treated skin area, unless your doctor tells you to. <br/>           Use Desoximetasone topical spray, 0.25% for the shortest amount of time needed to treat your plaque psoriasis. Tell your doctor if your skin condition is not getting better after 4 weeks of using desoximetasone topical spray, 0.25%. You should not use desoximetasone topical spray, 0.25% for longer than 4 weeks. <br/>           Do not use desoximetasone topical spray, 0.25% on your face, armpits or groin.<br/>           Do not use desoximetasone topical spray, 0.25% if you have thinning of your skin (atrophy) at the treatment site.<br/>           Wash your hands after applying desoximetasone topical spray, 0.25%. <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> What are the possible side effects of Desoximetasone Topical Spray, 0.25%? </content>
                              <br/>
                              <content styleCode="bold"> Desoximetasone topical spray, 0.25% may cause serious side effects, including:</content>
                              <br/>           <content styleCode="bold"> Symptoms of a disorder where the adrenal gland does not make enough of certain hormones (adrenal insufficiency) during treatment or after stopping treatment with desoximetasone topical spray, 0.25%. </content> Your doctor may do blood tests to check for adrenal gland problems. <br/>           <content styleCode="bold"> Cushing's syndrome,</content>  a condition that happens when your body is exposed to large amounts of the hormone cortisol. Your doctor may do tests to check for this.<br/>           <content styleCode="bold"> High blood sugar (hyperglycemia) or diabetes mellitus that has not been diagnosed can happen when treated with desoximetasone topical spray, 0.25%</content> . Your doctor may do tests to check for this.<br/>           <content styleCode="bold"> Skin reactions at the treated skin site</content> . Tell your doctor if you get any skin reactions or skin infections.<br/>           <content styleCode="bold"> Eye problems. </content> Using desoximetasone topical spray, 0.25% may increase your chance of getting cataracts and glaucoma. Do not get desoximetasone topical spray, 0.25% in your eyes because it may cause eye irritation. Tell your doctor if you have blurred vision or other vision problems during treatment with desoximetasone topical spray, 0.25%.<br/>
                              <br/>
                              <content styleCode="bold"> The most common side effects of Desoximetasone Topical Spray, 0.25% include </content> dryness, irritation and itching of skin at the treated site. <br/> These are not all of the possible side effects of desoximetasone topical spray, 0.25%. <br/> Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. <br/>
                              <br/> You may also report side effects to Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or visit our website at www.lupinpharmaceuticals.com.<br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> How should I store Desoximetasone Topical Spray, 0.25%? </content>
                              <br/>           Store desoximetasone topical spray, 0.25% at room temperature between 68˚F to 77˚F (20˚C to 25˚C). <br/>           Throw away (discard) unused desoximetasone topical spray, 0.25% after 30 days.<br/>
                              <content styleCode="bold"> Keep desoximetasone topical spray, 0.25% and all medicines out of the reach of children. </content>
                              <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> General information about the safe and effective use of Desoximetasone Topical Spray, 0.25%. </content>
                              <br/> Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use desoximetasone topical spray, 0.25% for a condition for which it was not prescribed. Do not give desoximetasone topical spray, 0.25% to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or doctor for information about desoximetasone topical spray, 0.25% that is written for health professionals. <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> What are the ingredients in Desoximetasone Topical Spray, 0.25%? </content>
                              <br/>
                              <content styleCode="bold"> Active ingredient: </content> desoximetasone USP<br/>
                              <content styleCode="bold"> Inactive ingredients: </content> butylated hydroxytoluene, citric acid anhydrous, diisopropyl adipate, isopropyl alcohol (23.4%), L-menthol, medium-chain triglycerides, mineral oil and sorbitan monooleate.<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID189">This Patient Information has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>LUPIN and the <renderMultiMedia referencedObject="IMGID1891"/> are registered trademarks of Lupin Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                  </paragraph>
                  <paragraph>Naples, FL 34108</paragraph>
                  <paragraph>United States</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Limited</content>
                  </paragraph>
                  <paragraph>Pithampur (M.P.) – 454 775</paragraph>
                  <paragraph>India</paragraph>
                  <paragraph>Revised: October 2024</paragraph>
                  <paragraph ID="ID191">
                     <content styleCode="bold">Instructions for Use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Desoximetasone Topical Spray, 0.25%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(des-OX-i-MET-a-sone)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important information: Desoximetasone topical spray, 0.25% is for use on skin (topical) only.</content> Do not get desoximetasone topical spray, 0.25% near or in your mouth, eyes or vagina.</paragraph>
                  <paragraph>Read the Instructions for Use before you start using desoximetasone topical spray, 0.25% and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Parts of Desoximetasone Topical Spray, 0.25% bottle (See Figure A) </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure A</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph ID="ID193">
                     <content styleCode="bold">How to apply Desoximetasone Topical Spray, 0.25%: </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 1: </content>Remove the cap from the pump top. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 2: </content>Hold the bottle in an upright position while pointing the opening of the pump top in the direction of the affected area. To spray, push down on the pump top. Apply desoximetasone topical spray, 0.25% to the affected area as instructed by your doctor. <content styleCode="bold">(See Figure B) </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure B</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph ID="ID195">
                     <content styleCode="bold">Step 3: </content>Spray only enough desoximetasone topical spray, 0.25% to cover the affected area, for example, the elbow (<content styleCode="bold">See Figure C</content>). Rub in desoximetasone topical spray, 0.25% gently to the affected area. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure C</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
                  <paragraph ID="ID197">Repeat Steps 2 and 3 to apply desoximetasone topical spray, 0.25% to other affected areas as instructed by your doctor. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 4: </content>After applying desoximetasone topical spray, 0.25%, place the cap back onto the pump top. (<content styleCode="bold">See Figure D</content>) </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure D</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
                  <paragraph ID="ID221">
                     <content styleCode="bold">How should I store desoximetasone topical spray, 0.25%?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID222" styleCode="Disc">
                     <item>Store desoximetasone topical spray, 0.25% at room temperature between 68˚F to 77˚F (20˚C to 25˚C).</item>
                     <item>Throw away (discard) unused desoximetasone topical spray, 0.25% 30 days after it has been opened.</item>
                     <item>Desoximetasone topical spray, 0.25% is flammable. Keep away from heat, flames or smoke.</item>
                  </list>
                  <paragraph ID="ID223">
                     <content styleCode="bold">Keep desoximetasone topical spray, 0.25% and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph ID="ID199">This Instructions for Use has been approved by the U.S. Food and Drug Administration. </paragraph>
                  <paragraph>LUPIN and the <renderMultiMedia referencedObject="IMGID1991"/> are registered trademarks of Lupin Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                  </paragraph>
                  <paragraph>Naples, FL 34108 </paragraph>
                  <paragraph>United States</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Limited</content>
                  </paragraph>
                  <paragraph>Pithampur (M.P.) – 454 775</paragraph>
                  <paragraph>India</paragraph>
                  <paragraph>Revised: October 2024                                                                                      ID#: 277395</paragraph>
               </text>
               <effectiveTime value="20250320"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="141068ee-85a2-40e4-a915-9ac149a5a57a-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="141068ee-85a2-40e4-a915-9ac149a5a57a-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>3</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="141068ee-85a2-40e4-a915-9ac149a5a57a-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>4</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="141068ee-85a2-40e4-a915-9ac149a5a57a-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="IMGID1891">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="141068ee-85a2-40e4-a915-9ac149a5a57a-189-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="IMGID1991">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="141068ee-85a2-40e4-a915-9ac149a5a57a-199-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID209">
               <id root="a200fd33-2027-49e1-965b-e3e9fc981911"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID205">
                     <content styleCode="bold">Desoximetasone Topical Spray, 0.25%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 mL Bottle Carton </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 68180-944-33</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Topical Use Only </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Not For Oral, Ophthalmic, or Intravaginal Use</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
                  <renderMultiMedia referencedObject="MM7"/>
               </text>
               <effectiveTime value="20250320"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>100 ml container</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="141068ee-85a2-40e4-a915-9ac149a5a57a-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>carton 100 ml</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="141068ee-85a2-40e4-a915-9ac149a5a57a-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>